175 results
Page 2 of 9
8-K
EX-10.1
t63czbha
26 Oct 22
Aravive Announces Approximately $41.5 Million Private Placement Financing
4:35pm
8-K
EX-99.1
75lbdwbmqvtn0mojs2
26 Oct 22
Aravive Announces Approximately $41.5 Million Private Placement Financing
4:35pm
8-K
EX-99.1
sfynf64 fj6
11 Oct 22
Aravive Receives Third Development Milestone from 3D Medicines
7:05am
8-K
EX-99.1
hwmbj021z0l 5uq
11 Aug 22
Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
7:15am
8-K
EX-10.3
nm8m0
3 Jun 22
Aravive Appoints Rudy Howard as Chief Financial Officer
4:06pm
8-K
3a90fzxq
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
EX-99.3
l11 20ld2d01cgw
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
EX-99.1
i37 zja5fc1wmhpo0
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
EX-99.2
gcogq3rvfi5sd
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
EX-99.1
rwc nvzxl5
12 May 22
Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates
7:05am
8-K
bqgqk8f
11 May 22
Regulation FD Disclosure
7:01am
8-K
EX-99.1
ifg1lt01vow 2o
31 Mar 22
Aravive Reports Fourth Quarter and Full Year 2021
4:05pm
8-K
EX-10.1
ff7q9 giym2s8
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
8-K
EX-10.2
6nbzvs9
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
424B5
7v6wg8fgfcqdadp qk8
31 Mar 22
Prospectus supplement for primary offering
6:06am
8-K
EX-99.1
8rjby7cw j9c6xkr
3 Mar 22
Aravive Announces Positive Updated Data and New Biomarker Data
7:06am
8-K
EX-99.1
mo2pu62t8 32pmt
31 Jan 22
Aravive Announces First Patient Dosed in Phase 2 Study
7:05am